Price and Volume Movers
Vericel Corporation (NASDAQ:VCEL) surged over 57% on 112x average volume. The company announced that the FDA has approved MACI for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The FDA actually released a press release on Tuesday evening with the news, causing a flood of activity in yesterday’s evening session but the company waited until pre-market today to issue its press release.
Alcobra Ltd. (Nasdaq:ADHD) announced today that it met with the FDA to discuss its clinical hold of Metadoxine Extended Release (MDX). It expects to provide further details regarding the MDX regulatory path upon receipt of final meeting minutes from the FDA in the coming weeks. Shares pared losses to close down 4% on 5x average volume after being down over 12% until late in the session.
Proteon Therapeutics, Inc. (Nasdaq:PRTO) shares continued to drop on Wednesday with shares falling a further 14% on 10x average volume. The company announced yesterday that its first Phase 3 trial of vonapanitase (PATENCY-1) did not meet its primary endpoint.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced after hours that it intends to offer $225m of convertible senior notes. Shares are currently down 10% in the after-hours session.
Shares of vTv Therapeutics Inc (NASDAQ:VTVT) are currently up 15% in the after-hours session following its release of Phase 2 data of TTP273 for the treatment of Type 2 diabetes. Although full data were not released the company did note that “TTP273 demonstrated a statistically significant reduction in HbA1c.”
Shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) shares surged 22% on 100x average volume following presentation of new data from its Phase 2 study of NurOwn in ALS (amyotrophic lateral sclerosis).
Other price movers (+10%):
Northwest Biotherapeutics, Inc (NASDAQ:NWBO): +21%; 6x average volume.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX): +14%; 3x average volume.
MacroGenics Inc (NASDAQ:MGNX): -15%; 4x average volume. RXi Pharmaceuticals Corp (NASDAQ:RXII): -11%.
aTyr Pharma Inc (NASDAQ:LIFE): -11%; 2.5x average volume.
Full pipeline updates below: